TB diagnostic

Grant of a patent has been awarded to PBD Biotech for its Actiphage diagnostic for incipient tuberculosis in South Africa, this complements the regional West Africa patent gained earlier this year.

Actiphage TB is to enter its third clinical trial, which is aimed at validating its utility as a tuberculosis diagnostic. The phage-based diagnostic has potential for detecting TB progression.

The bacteriophage-based diagnostic may play vital role in detecting TB progression

PBD Biotech to speak at Liverpool School of Tropical Medicine anniversary celebrations

The UK’s first Centre for Phage Research is being officially launched on 16th May and featured in the UK KTN UK Phage Innovation Showcase will be Actiphage®, a phage-based molecular diagnostic for tuberculosis.

PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual Property Organization (OAPI). This covers the mainly French-speaking countries of West Africa.

PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.

Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech, developers of Actiphage - a rapid blood test for early-stage active tuberculosis - is partnering with the Rapid Research in...

A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.

Sub-Saharan Africa is devastated by TB disease. Zambia, has a high TB/HIV burden – 59,000 people developed TB in 2020 and 15,000 died. There is a critical need for a non-sputum based rapid test for diagnosing TB disease.

PBD Biotech Limited is pleased to announce that its key technology patent has been granted by the European Patent Office.